journal article·2023-11-14

Golgi Apparatus-Targeted Photodynamic Therapy for Enhancing Tumor Immunogenicity by Eliciting NLRP3 Protein-Dependent Pyroptosis

Zhi-Chao Hu, Ben Wang, Xiao-Gang Zhou, Hai-Feng Liang, Bing Liang, Hong-Wei Lu, Yu-Xiang Ge, Qing Chen, Qi-Wei Tian, Feng-Feng Xue, Li-Bo Jiang, Jian Dong

ACS Nano· Volume 17· Issue 21
Publisher page

Abstract

Innate and adaptive immunity is important for initiating and maintaining immune function. The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome serves as a checkpoint in innate and adaptive immunity, promoting the secretion of pro-inflammatory cytokines and gasdermin D-mediated pyroptosis. As a highly inflammatory form of cell death distinct from apoptosis, pyroptosis can trigger immunogenic cell death and promote systemic immune responses in solid tumors. Previous studies proposed that NLRP3 was activated by translocation to the mitochondria. However, a recent authoritative study has challenged this model and proved that the Golgi apparatus might be a prerequisite for the activation of NLRP3. In this study, we first developed a Golgi apparatus-targeted photodynamic strategy to induce the activation of NLRP3 by precisely locating organelles. We found that Golgi apparatus-targeted photodynamic therapy could significantly upregulate NLRP3 expression to promote the subsequent release of intracellular proinflammatory contents such as IL-1β or IL-18, creating an inflammatory storm to enhance innate immunity. Moreover, this acute NLRP3 upregulation also activated its downstream classical caspase-1-dependent pyroptosis to enhance tumor immunogenicity, triggering adaptive immunity. Pyroptosis eventually led to immunogenic cell death, promoted the maturation of dendritic cells, and effectively activated antitumor immunity and long-lived immune memory. Overall, this Golgi apparatus-targeted strategy provided molecular insights into the occurrence of immunogenic pyroptosis and offered a platform to remodel the tumor microenvironment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Heme Oxygenase-1 and Carbon Monoxide · Histiocytic Disorders and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Department of Orthopedic Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

Department of Orthopedic Surgery, Minhang Hospital, Fudan University, Shanghai 201100, China

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China

Funding

Natural Science Foundation of Shanghai Municipality · Shanghai Key Laboratory of Molecular Imaging · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Shanghai Municipal Health Commission · Shanghai Rising-Star Program · Shanghai Talent Development Fund

References (67)

Show source-provided references
1. 10.1016/S0140-6736(21)00312-310.1016/S0140-6736(21)00312-3 ↗
2. 10.1038/s41591-021-01450-210.1038/s41591-021-01450-2 ↗
3. 10.1053/ctrv.2000.021010.1053/ctrv.2000.0210 ↗
4. 10.3171/jns.1983.59.1.011110.3171/jns.1983.59.1.0111 ↗
5. 10.1053/j.seminoncol.2007.12.00510.1053/j.seminoncol.2007.12.005 ↗
6. 10.1097/BRS.000000000000281610.1097/BRS.0000000000002816 ↗
7. 10.1016/j.cej.2021.13213110.1016/j.cej.2021.132131 ↗
8. 10.2106/JBJS.N.0112410.2106/JBJS.N.01124 ↗
9. Wu X. G. · Eur. Rev. Med. Pharmacol. Sci. · 2022 · 26 · 1683
10. 10.1016/j.ejca.2018.08.02810.1016/j.ejca.2018.08.028 ↗
11. 10.1177/030006051988810710.1177/0300060519888107 ↗
12. 10.1186/s12951-021-00975-510.1186/s12951-021-00975-5 ↗
13. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
14. 10.1016/j.intimp.2020.10624710.1016/j.intimp.2020.106247 ↗
15. 10.1016/j.bioactmat.2022.07.01610.1016/j.bioactmat.2022.07.016 ↗
16. 10.7150/ijbs.6029210.7150/ijbs.60292 ↗
17. 10.1002/ctm2.49210.1002/ctm2.492 ↗
18. 10.1002/advs.20220291410.1002/advs.202202914 ↗
19. 10.1038/s41419-019-1412-910.1038/s41419-019-1412-9 ↗
20. 10.1016/j.intimp.2018.12.01910.1016/j.intimp.2018.12.019 ↗
21. 10.1038/s41419-019-2157-110.1038/s41419-019-2157-1 ↗
22. 10.1038/nature1551410.1038/nature15514 ↗
23. 10.4049/jimmunol.160069910.4049/jimmunol.1600699 ↗
24. 10.15252/embj.20169469610.15252/embj.201694696 ↗
25. 10.1016/j.phrs.2021.10574810.1016/j.phrs.2021.105748 ↗
26. 10.1186/s12931-014-0087-010.1186/s12931-014-0087-0 ↗
27. 10.1038/cr.2015.13910.1038/cr.2015.139 ↗
28. 10.1038/nri.2015.710.1038/nri.2015.7 ↗
29. 10.1074/jbc.M112.40713010.1074/jbc.M112.407130 ↗
30. 10.4049/jimmunol.110061310.4049/jimmunol.1100613 ↗
31. 10.1038/s41586-018-0761-310.1038/s41586-018-0761-3 ↗
32. 10.1093/intimm/13.3.35910.1093/intimm/13.3.359 ↗
33. 10.3390/cells1012359410.3390/cells10123594 ↗
34. 10.1021/acsnano.8b0692410.1021/acsnano.8b06924 ↗
35. 10.1021/acsnano.9b0416610.1021/acsnano.9b04166 ↗
36. 10.1039/C6CS00616G10.1039/C6CS00616G ↗
37. 10.1016/j.jconrel.2021.04.03110.1016/j.jconrel.2021.04.031 ↗
38. 10.1038/ni.198010.1038/ni.1980 ↗
39. 10.1016/j.immuni.2012.01.00910.1016/j.immuni.2012.01.009 ↗
40. 10.1038/ni.183110.1038/ni.1831 ↗
41. 10.1002/adfm.20221449910.1002/adfm.202214499 ↗
42. 10.1016/j.carbpol.2019.11556810.1016/j.carbpol.2019.115568 ↗
43. 10.1016/j.trac.2022.11671410.1016/j.trac.2022.116714 ↗
44. 10.1039/D1NR01552D10.1039/D1NR01552D ↗
45. 10.1016/j.carbpol.2020.11688710.1016/j.carbpol.2020.116887 ↗
46. 10.1016/j.biomaterials.2020.12013810.1016/j.biomaterials.2020.120138 ↗
47. 10.1080/07391102.2017.134133710.1080/07391102.2017.1341337 ↗
48. 10.1016/j.ecoenv.2023.11526210.1016/j.ecoenv.2023.115262 ↗
49. 10.1186/s13046-021-02065-810.1186/s13046-021-02065-8 ↗
50. 10.1111/cas.1505910.1111/cas.15059 ↗
51. 10.1111/imr.1253410.1111/imr.12534 ↗
52. 10.1016/j.ebiom.2019.05.03610.1016/j.ebiom.2019.05.036 ↗
53. 10.1016/j.biomaterials.2021.12116710.1016/j.biomaterials.2021.121167 ↗
54. 10.1093/intimm/dxs16110.1093/intimm/dxs161 ↗
55. 10.1016/j.cej.2021.12865910.1016/j.cej.2021.128659 ↗
56. 10.1002/adma.20180300110.1002/adma.201803001 ↗
57. 10.1016/j.cej.2022.13726910.1016/j.cej.2022.137269 ↗
58. 10.1002/adhm.20220093810.1002/adhm.202200938 ↗
59. 10.1002/smll.20210778710.1002/smll.202107787 ↗
60. 10.1038/s41422-018-0090-y10.1038/s41422-018-0090-y ↗
61. 10.1158/2326-6066.CIR-13-010210.1158/2326-6066.CIR-13-0102 ↗
62. 10.1016/j.biomaterials.2022.12140710.1016/j.biomaterials.2022.121407 ↗
63. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
64. 10.1016/j.materresbull.2013.03.04010.1016/j.materresbull.2013.03.040 ↗
65. 10.1016/j.taap.2009.08.01010.1016/j.taap.2009.08.010 ↗
66. 10.1016/j.dyepig.2018.04.00810.1016/j.dyepig.2018.04.008 ↗
67. 10.1016/j.biomaterials.2021.12091710.1016/j.biomaterials.2021.120917 ↗